163074-98-4 Usage
Uses
Used in Organic Synthesis:
[(3aR,4R,5R,6aS)-hexahydro-2-oxo-5-(phenylmethoxy)-2H-cyclopenta[b]furan-4-carboxaldehyde] is used as an intermediate in organic synthesis for the creation of more complex molecules. Its unique structure and functional groups allow for further chemical modification, making it a versatile building block for the synthesis of various compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, [(3aR,4R,5R,6aS)-hexahydro-2-oxo-5-(phenylmethoxy)-2H-cyclopenta[b]furan-4-carboxaldehyde] is used as a starting material for the development of novel drugs. Its complex structure and functional groups offer opportunities for exploring its biological activities and potential therapeutic applications.
Used in Agrochemicals:
[(3aR,4R,5R,6aS)-hexahydro-2-oxo-5-(phenylmethoxy)-2H-cyclopenta[b]furan-4-carboxaldehyde] may also be utilized in the agrochemical industry as a precursor for the development of new pesticides or other agricultural chemicals. Its unique structure could provide new modes of action or improved efficacy in these applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, [(3aR,4R,5R,6aS)-hexahydro-2-oxo-5-(phenylmethoxy)-2H-cyclopenta[b]furan-4-carboxaldehyde] is used as a research compound for exploring its potential as a therapeutic agent. Its complex structure and functional groups may offer new avenues for drug discovery and the development of innovative treatments for various diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 163074-98-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,3,0,7 and 4 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 163074-98:
(8*1)+(7*6)+(6*3)+(5*0)+(4*7)+(3*4)+(2*9)+(1*8)=134
134 % 10 = 4
So 163074-98-4 is a valid CAS Registry Number.
163074-98-4Relevant academic research and scientific papers
Method for large-scale preparation of tafluprost
-
Paragraph 0019; 0020, (2021/01/24)
The invention discloses a method for industrially preparing tafluprost. The method comprises the following steps: taking Corey lactone as an initial raw material, oxidizing, condensing, fluorinating,deprotecting, reducing, re-condensing, esterifying and r
POLYMORPHIC FORMS OF LUBIPROSTONE
-
Page/Page column 11-12, (2011/08/21)
There is provided a crystalline form of Lubiprostone, termed APO-II and methods for making APO-II. APO-II is a polymorphic form of Lubiprostone.
METHODS OF MAKING LUBIPROSTONE AND INTERMEDIATES THEREOF
-
Page/Page column 39, (2010/08/08)
There is provided processes for preparing Lubiprostone and intermediates thereof. Also provided are compounds, including intermediates for preparing Lubiprostone as well as compositions comprising Lubiprostone and other compounds, including intermediates for preparing Lubiprostone and other compounds. (I)
